PolyPeptide Shortlists EQT, IDG in $1.6 Billion Sale Process
Updated
Updated · Bloomberg · May 18
PolyPeptide Shortlists EQT, IDG in $1.6 Billion Sale Process
1 articles · Updated · Bloomberg · May 18
$1.6 billion PolyPeptide has advanced EQT AB and IDG Capital to the next bidding round for the Swiss contract drugmaker, according to people familiar with the matter.
Altaris LLC is also pursuing the company, indicating competition remains active even after the shortlist was set.
The sale process follows a recent rally in PolyPeptide shares that lifted its market value to about $1.6 billion, though the stock still remains below peaks reached roughly four years ago.
Is the race to acquire peptide makers a strategic masterstroke or a high-stakes bubble fueled by the weight-loss drug frenzy?
Beyond factory expansions, could a shortage of skilled chemists derail the global supply of blockbuster drugs for diabetes and obesity?